«The treatment of
multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical
multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with
tumor cells»
protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper
Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical
Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School.
Whereas earlier, unsuccessful cancer vaccines usually targeted a single distinctive cancer
protein shared among patients, these new ones contain
multiple mutated
proteins, or «neoantigens,» that are specific to an individual patient's
tumor.